Product Description
The study medication, elimusertib, works by blocking a substance (ATR Kinase) which is produced by the body and is important for the growth of tumor cells. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04095273)
Mechanisms of Action: ATR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Japan, Singapore, Switzerland, United States, Unknown Location
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Ataxia Telangiectasia|Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20182524 | P1 |
Completed |
Lymphoma |
2023-09-13 |
2025-04-29 |
Patient Enrollment|Treatments |
|
| JapicCTI-183998 | P1 |
Active |
Lymphoma|Ataxia Telangiectasia |
2023-02-15 |